Oncology

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.

News

GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.

News

Researchers have developed an AI that could help doctors predict a patient's chance of surviving cancer – and potentially guide treatment decisions.

News

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi in early bladder cancer.

News

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.

News

A planning application has been filed to invest £1bn in "the world's leading centre for cancer research and treatment" in a London borough.